Logo

Bayer Reports Data from the P-III (OASIS 3) Trial of Elinzanetant for Treating Vasomotor Symptoms in Postmenopausal Women

Share this
Bayer

Bayer Reports Data from the P-III (OASIS 3) Trial of Elinzanetant for Treating Vasomotor Symptoms in Postmenopausal Women

Shots:

  • The P-III (OASIS 3) trial assesses elinzanetant’s (120mg, oral, QD) safety & efficacy vs PBO to treat vasomotor symptoms in postmenopausal women (n=628, 40yrs. to 65yrs.) over 52wks. in 83 sites across 9 countries
  • The study reached its 1EP depicting the reduced frequency of moderate to severe vasomotor symptoms from baseline to wk.12 and a consistent safety profile with prior studies was seen over 52wks.
  • Additionally, Bayer previously reported results from the 2 P-III (OASIS 1 & OASIS 2) programs that reached the 1EPs and 2EPs. The results from all three studies will be highlighted at future scientific congresses and will form the basis of marketing authorizations for elinzanetant to treat VMS

Ref: Bayer | Image: Bayer

Related News:- Bayer Partners with Aignostics to Strengthen its Precision Oncology Portfolio

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions